ReviewEuropean radiology experimental2021
Advances in liver US, CT, and MRI: moving toward the future.
Review in European radiology experimental, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Artificial intelligence prognostication of liver disease using imaging.The British journal of radiology · 2026Review
- Hepatic artery augmented velocity index and steatosis/fibrosis in MAFLD.Abdominal radiology (New York) · 2026Article
- Hepatic and abdominal adiposity in type 2 diabetes as assessed with machine learning on computed tomography scans.Diabetes, obesity & metabolism · 2026Article
- Article
- A preclinical CT and MRI Liver Imaging Dataset with Anatomical, Functional and Segmentation Data.Scientific data · 2026Article
- [Clinical features and pathological scoring analysis of hepatic amyloidosis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Article
- Natural language processing and LLMs in liver imaging: a practical review of clinical applications.Abdominal radiology (New York) · 2026Review
- A review of established and new developments in local therapies for liver cancer.ESMO gastrointestinal oncology · 2026Review
- Imaging-based fibrosis assessment and risk stratification in MASLD.Frontiers in medicine · 2026Review
- Enhanced preoperative prediction for microvascular invasion in hepatocellular carcinoma through an optimized MR Radiomics combination strategy and machine learning predictor.Frontiers in medicine · 2026Article
- Research advances in the diagnosis and treatment of MASLD/MASH.Annals of medicine · 2025Review
- Extra-hepatic arterial branching pattern in the common marmoset (Callithrix jacchus).Anatomical science international · 2025Article
- Images Versus Videos in Contrast-Enhanced Ultrasound for Computer-Aided Diagnosis.Sensors (Basel, Switzerland) · 2025Article
- Recent Advances in Magnetic Resonance Imaging for the Diagnosis of Liver Cancer: A Comprehensive Review.Diagnostics (Basel, Switzerland) · 2025Review
- Alkaline Phosphatase-Targeted, Gadolinium-Labeled Nanoparticles for Enhanced Multimodal Imaging of Liver Cancer.ACS applied materials & interfaces · 2025Article
- Efficacy of magnetic resonance imaging in managing glycogen storage disease.Orphanet journal of rare diseases · 2025Article
- Unrecognised rural-urban disparities in epidemiology of metabolic-associated fatty liver disease in the representative area of China.BMJ nutrition, prevention & health · 2025Article
- Organotropic metastasis in colorectal cancer: integrating molecular pathways with therapeutic opportunities.Frontiers in immunology · 2025Review
- Review
- New Biomarkers in Liver Fibrosis: A Pass through the Quicksand?Journal of personalized medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past two decades, the epidemiology of chronic liver disease has changed with an increase in the prevalence of nonalcoholic fatty liver disease in parallel to the advent of curative treatments for hepatitis C. Recent developments provided new tools for diagnosis and monitoring of liver diseases based on ultrasound (US), computed tomography (CT), and magnetic resonance imaging (MRI), as applied for assessing steatosis, fibrosis, and focal lesions. This narrative review aims to discuss the emerging approaches for qualitative and quantitative liver imaging, focusing on those expected to become adopted in clinical practice in the next 5 to 10 years. While radiomics is an emerging tool for many of these applications, dedicated techniques have been investigated for US (controlled attenuation parameter, backscatter coefficient, elastography methods such as point shear wave elastography [pSWE] and transient elastography [TE], novel Doppler techniques, and three-dimensional contrast-enhanced ultrasound [3D-CEUS]), CT (dual-energy, spectral photon counting, extracellular volume fraction, perfusion, and surface nodularity), and MRI (proton density fat fraction [PDFF], elastography [MRE], contrast enhancement index, relative enhancement, T1 mapping on the hepatobiliary phase, perfusion). Concurrently, the advent of abbreviated MRI protocols will help fulfill an increasing number of examination requests in an era of healthcare resource constraints.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.